Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.135
+0.155 (3.89%)
At close: Nov 21, 2024, 4:00 PM
4.150
+0.015 (0.36%)
After-hours: Nov 21, 2024, 4:22 PM EST
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
42
Market Cap
134.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | 125.00K | - | - |
| Dec 31, 2019 | 125.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 59.85M |
| Innate Pharma | 36.20M |
| Zomedica | 26.73M |
| Cibus | 4.15M |
| Avalo Therapeutics | 820.00K |
| Cardiff Oncology | 688.00K |
| Inhibikase Therapeutics | 1.00 |
CADL News
- 16 days ago - Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma - GlobeNewsWire
- 20 days ago - Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think - Seeking Alpha
- 6 weeks ago - Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - GlobeNewsWire
- 4 months ago - 3 Biotech Names With Potential Catalysts By Year End - Seeking Alpha
- 5 months ago - Candel Therapeutics to Join Russell 3000® Index - GlobeNewsWire
- 6 months ago - FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma - GlobeNewsWire
- 6 months ago - Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting - GlobeNewsWire
- 6 months ago - Candel Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire